A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab/hyaluronidase (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma; Plasmacytoma
- Focus Therapeutic Use
- Acronyms Perseus
- 07 Apr 2025 According to a Johnson & Johnson media release, company announced that the European Commission (EC) has approved an indication extension of DARZALEX (daratumumab) subcutaneous (SC) formulation in the frontline setting. The approval is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on result of this trial.
- 25 Oct 2024 According to a Johnson & Johnson media release, announced that the European Commission (EC) approved the indication extension for DARZALEX (daratumumab) subcutaneous (SC) formulation in combination with bortezomib, lenalidomide and dexamethasone (daratumumab-VRd) in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant. This approval is supported by data from the Phase 3 PERSEUS study.
- 27 Sep 2024 According to a Johnson & Johnson Media Release, results from this study will be presented in an oral presentation at IMS